TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from ImmuPharma ( (GB:IMM) ) is now available.
ImmuPharma PLC has announced the posting of its Notice of Annual General Meeting (AGM) and Annual Report and Accounts for the year ended December 31, 2024, to its shareholders. The AGM is scheduled for June 12, 2025, at The Malmaison Hotel in London. This announcement is a routine part of the company’s governance and provides shareholders with essential information regarding the company’s financial performance and strategic direction.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. Its portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives, with a lead program, P140, targeting Systemic Lupus Erythematosus (SLE) and Chronic Idiopathic Demyelinating Polyneuropathy (CIDP).
Average Trading Volume: 3,116,513
Technical Sentiment Signal: Buy
Current Market Cap: £14.97M
For an in-depth examination of IMM stock, go to TipRanks’ Stock Analysis page.